Gyre Therapeutics, Inc. Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements
Gyre Therapeutics, Inc. (GYRE) reported Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements of 13.75 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Notes
us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements · last filed 2026-08-07
- Gyre Therapeutics, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2025-09-30 was 13.11M shares, a 21.83% decline year-over-year.
- Gyre Therapeutics, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2025-06-30 was 13.50M shares, a 17.96% decline year-over-year.
- Gyre Therapeutics, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2025-03-31 was 15.37M shares, a 8.98% decline year-over-year.
- Gyre Therapeutics, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2024-09-30 was 16.77M shares, a 9.46% increase year-over-year.
- Gyre Therapeutics, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2025 was 13.75M shares, a 16.19% decline from fiscal 2024.
- Gyre Therapeutics, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2024 was 16.41M shares.
- Gyre Therapeutics, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2022 was 12.10M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 3 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 6 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 6 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 9 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | 13.75M shares 10-K · filed 2026-03-13 | |||||
| 2025-09-30 | 13.11M shares 10-Q · filed 2025-11-07 | 14.01M shares 10-Q · filed 2025-11-07 | ||||
| 2025-06-30 | 13.50M shares 10-Q · filed 2025-08-11 | 0.00 shares 10-Q · filed 2026-08-07 | 14.44M shares 10-Q · filed 2025-08-11 | |||
| 2025-03-31 | 15.37M shares 10-Q · filed 2026-05-08 | |||||
| 2024-12-31 | 16.41M shares 10-K · filed 2026-03-13 | |||||
| 2024-09-30 | 16.77M shares 10-Q · filed 2025-11-07 | 16.72M shares 10-Q · filed 2025-11-07 | ||||
| 2024-06-30 | 16.45M shares 10-Q · filed 2025-08-11 | 16.69M shares 10-Q · filed 2025-08-11 | ||||
| 2024-03-31 | 16.89M shares 10-Q · filed 2025-05-09 | |||||
| 2023-09-30 | 15.32M shares 10-Q · filed 2024-11-13 | 15.32M shares 10-Q · filed 2024-11-13 | ||||
| 2023-06-30 | 15.32M shares 10-Q · filed 2024-08-13 | 15.32M shares 10-Q · filed 2024-08-13 | ||||
| 2023-03-31 | 15.33M shares 10-Q · filed 2024-05-13 | 225.91K shares 10-Q · filed 2023-05-15 | ||||
| 2022-12-31 | 12.10M shares 10-K · filed 2024-03-27 | |||||
| 2022-09-30 | 133.17K shares 10-Q · filed 2023-10-26 | |||||
| 2022-06-30 | 5.87K shares 10-Q · filed 2023-08-14 | 2.94K shares 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |